{
    "clinical_study": {
        "@rank": "45298", 
        "arm_group": [
            {
                "arm_group_label": "EGFR patients", 
                "arm_group_type": "Experimental", 
                "description": "ipilimumab and erlotinib in EGFR mutated patients"
            }, 
            {
                "arm_group_label": "ALK patients", 
                "arm_group_type": "Experimental", 
                "description": "ipilimumab and crizotinib in ALK mutated patients"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a modified phase I trial of ipilimumab in combination with mutation - specific\n      targeted therapy (crizotinib or erlotinib) at conventional doses stratified for presence of\n      ALK (Anaplastic lymphoma kinase) or EGFR (epidermal growth factor receptor) mutation.\n      Ipilimumab will be tested at a single level of 3 mg/kg for both ALK and EGFR mutated groups\n      with expansion cohorts for each group to better characterize long term effects of\n      combination therapy.\n\n      The goals of the overall study are to evaluate a recommended phase 2 dose and the short and\n      long term toxicities of the combinations."
        }, 
        "brief_title": "Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC)\n             that is either EGFR or ALK mutated.\n\n          -  Untreated with/or actively treated with specific inhibitor for less than 6 months if\n             not progressing on active therapy.\n\n          -  Age > 18.\n\n          -  ECOG performance status 0, 1 or 2.\n\n          -  Prior chemotherapy is allowed if > one month. Patients must not have received\n             chemotherapy within 4 weeks of the start of study drug.\n\n          -  Brain metastases are allowed if the patient is asymptomatic or previous steroid\n             treatment was discontinued > 6 weeks.\n\n          -  Adequate bone marrow function as defined by:\n\n               -  White Blood Count (WBC) > 2.0 g/dL\n\n               -  Hemoglobin > 9.0 g/dL\n\n               -  Absolute neutrophil count (ANC) > 1,000/mm3\n\n               -  Platelets > 100,000/mm3\n\n          -  Serum bilirubin levels < 1.5 mg/dL except for patients with Gilbert's syndrome.\n\n          -  Adequate organ function as defined by:\n\n               -  Serum aspartate transaminase (AST) < 2.5 X upper limit of normal.\n\n               -  Serum alanine transaminase (ALT) < 2.5 X upper limit of normal.\n\n          -  If female and of childbearing potential, documentation of negative pregnancy test\n             (serum or urine) within 7 days prior to first dose.\n\n          -  Able to provide informed consent and have signed an approved consent form that\n             conforms to federal and institutional guidelines.\n\n        Exclusion Criteria:\n\n          -  Concurrent therapy with any other non-protocol anti-cancer therapy.\n\n          -  History of any other malignancy requiring active treatment.\n\n          -  Patients who have had a history of acute diverticulitis, intra-abdominal abscess,\n             Gastrointestical obstruction and abdominal carcinomatosis which are known risk\n             factors for bowel perforation.\n\n          -  History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic\n             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune\n             vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of\n             autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo and adequately\n             controlled endocrine deficiencies such as hypothyroidism are allowed.\n\n          -  Significant cardiovascular disease including:\n\n               -  Active, clinically symptomatic left ventricular failure.\n\n               -  Uncontrolled symptomatic hypertension that cannot be controlled with\n                  anti-hypertensive agents.\n\n               -  Myocardial infarction, severe angina, or unstable angina within 6 months prior\n                  to administration of first dose of study drug.\n\n               -  History of serious ventricular arrhythmia (i.e., ventricular tachycardia or\n                  ventricular fibrillation)\n\n               -  Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial\n                  fibrillation that is well controlled with anti-arrhythmic medication)\n\n               -  Coronary or peripheral artery bypass graft within 6 months of screening.\n\n          -  Uncontrolled CNS metastases are not allowed; subjects with previously treated brain\n             metastases will be allowed if the brain metastases have been treated, toxicities have\n             resolved to grade 1 or baseline and steroids are no longer required. Leptomeningeal\n             metastases are not allowed.\n\n          -  Serious/active infection or infection requiring parenteral antibiotics.\n\n          -  Pregnant or lactating females.\n\n          -  HIV infection or chronic hepatitis B or C. Negative Screening tests for HIV,\n             Hepatitis B, and Hepatitis C are required.\n\n          -  The presence of any other medical or psychiatric disorder that, in the opinion of the\n             treating physician, would contraindicate the use of the drugs in this protocol or\n             place the subject at undue risk for treatment complications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998126", 
            "org_study_id": "HCI66705"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "EGFR patients", 
                    "ALK patients"
                ], 
                "description": "Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "Yervoy"
            }, 
            {
                "arm_group_label": "EGFR patients", 
                "description": "Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ALK patients", 
                "description": "Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)", 
                "intervention_name": "Crizotinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84112"
                }, 
                "name": "Huntsman Cancer Institute"
            }, 
            "investigator": {
                "last_name": "Wallace Akerley, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts", 
        "overall_contact": {
            "email": "vicki.lester@hci.utah.edu", 
            "last_name": "Vicki Lester", 
            "phone": "801-585-7844"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor  dynamics of ipilimumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.\nIn this study, immune-related response criteria (irRC) will be used to assess subject response to study treatment per investigator assessment. The secondary endpoint irPFS will be determined based on investigator assessment. In order to adequately address this secondary objective, investigators will follow the clinical practice guidelines to obtain additional tumor assessments beyond mWHO PD and follow the instructions in this section for the determination of immune-related response.", 
            "measure": "toxicity of ipilimumab and erlotinib in EGFR mutated patients and toxicity of ipilimumab and crizotinib in ALK mutated patients with Non-small cell lung cancer", 
            "safety_issue": "Yes", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998126"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor  dynamics of ipilimumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.\nIn this study, immune-related response criteria (irRC) will be used to assess subject response to study treatment per investigator assessment. The secondary endpoint irPFS will be determined based on investigator assessment. In order to adequately address this secondary objective, investigators will follow the clinical practice guidelines to obtain additional tumor assessments beyond mWHO PD and follow the instructions in this section for the determination of immune-related response.", 
                "measure": "immune function pre and post immune therapy", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "University of Utah", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Utah", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}